The medication is formulated and licensed exclusively for subcutaneous use, as clearly stated in the Summary of Product Characteristics
Sustained weight loss with semaglutide once-weekly treatment as add-on to standard of care in overweight or obese subjects: A phase 3a trial
The free 15-minute phone consult tells us whether youre a good candidate
It has been suggested that BPC-157 therapy might recover many muscle disabilities, including those caused by traumatic brain injury, severe electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome, and NO-system blockade
Strategic shift: Novo Nordisk is actively winding down legacy and lower-margin insulin products, especially in developed markets, to prioritize next-generation basal insulins (Tresiba, Awiqli) and innovative GLP-1 therapies